TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+13.63%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.76B
AUM Growth
+$2.76B
(+4.6%)
Cap. Flow
-$175M
Cap. Flow
% of AUM
-6.35%
Top 10 Holdings %
Top 10 Hldgs %
38.62%
Holding
217
New
37
Increased
33
Reduced
47
Closed
5
Top Buys
| 1 |
Zoetis
ZTS
|
$17.5M |
| 2 |
Johnson & Johnson
JNJ
|
$14.4M |
| 3 |
Elevance Health
ELV
|
$8.36M |
| 4 |
Novo Nordisk
NVO
|
$7.83M |
| 5 |
Thermo Fisher Scientific
TMO
|
$6.76M |
Top Sells
| 1 |
Merck
MRK
|
$45.3M |
| 2 |
Pfizer
PFE
|
$44.3M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$33.4M |
| 4 |
UnitedHealth
UNH
|
$21.5M |
| 5 |
Eli Lilly
LLY
|
$18.6M |
Sector Composition
| 1 | Healthcare | 93.74% |
| 2 | Real Estate | 2.75% |
| 3 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $150M | 5.44% | 1,942,317 -121,382 | -6% | -$9.37M |
|
2
Amgen
AMGN
$155B
| $141M | 5.1% | 677,855 -22,733 | -3% | -$4.71M |
|
3
Biogen
BIIB
$19.4B
| $138M | 5.02% | 391,402 -12,553 | -3% | -$4.44M |
|
|
4
Johnson & Johnson
JNJ
$427B
| $138M | 5% | 996,968 +103,886 | +12% | +$14.4M |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $117M | 4.26% | 1,312,350 +60,880 | +5% | +$5.45M |
|
|
6
UnitedHealth
UNH
$281B
| $91.6M | 3.32% | 344,486 -80,831 | -19% | -$21.5M |
|
7
Illumina
ILMN
$15.8B
| $89.1M | 3.23% | 242,717 -41,775 | -15% | -$15.3M |
|
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $78.7M | 2.85% | 408,235 -173,287 | -30% | -$33.4M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $60.9M | 2.21% | 438,416 | – | – |
|
10
Viatris
VTRS
$12.3B
| $60.6M | 2.2% | 1,657,017 | – | – |
|
|
11
Pfizer
PFE
$141B
| $59.7M | 2.16% | 1,354,093 -1,005,594 | -43% | -$44.3M |
|
12
Regeneron Pharmaceuticals
REGN
$61.5B
| $59.1M | 2.14% | 146,237 | – | – |
|
|
AGN
13
DELISTED
Allergan plc
AGN
| $47.4M | 1.72% | 248,836 | – | – |
|
14
AbbVie
ABBV
$372B
| $46.5M | 1.69% | 492,078 -21,580 | -4% | -$2.04M |
|
|
15
Merck
MRK
$210B
| $45.8M | 1.66% | 645,208 -638,814 | -50% | -$45.3M |
|
16
Incyte
INCY
$16.5B
| $44.6M | 1.62% | 645,442 | – | – |
|
|
17
Thermo Fisher Scientific
TMO
$186B
| $44M | 1.6% | 180,395 +27,700 | +18% | +$6.76M |
|
|
18
Elevance Health
ELV
$71.8B
| $38.7M | 1.4% | 141,147 +30,514 | +28% | +$8.36M |
|
19
Sarepta Therapeutics
SRPT
$1.78B
| $36M | 1.31% | 223,182 -11,307 | -5% | -$1.83M |
|
20
Medtronic
MDT
$119B
| $33.4M | 1.21% | 339,439 -84,254 | -20% | -$8.29M |
|
21
CVS Health
CVS
$92.8B
| $31.6M | 1.15% | 401,101 +34,580 | +9% | +$2.72M |
|
22
Abbott
ABT
$231B
| $28.7M | 1.04% | 391,719 -235,300 | -38% | -$17.3M |
|
23
Stryker
SYK
$150B
| $28.5M | 1.03% | 160,432 +23,801 | +17% | +$4.23M |
|
24
AstraZeneca
AZN
$248B
| $28.4M | 1.03% | 718,624 -60,264 | -8% | -$2.38M |
|
25
Novartis
NVS
$245B
| $27.8M | 1.01% | 322,690 +26,870 | +9% | +$2.32M |
|